2 insiders at Inhibrx Biosciences, Inc. just bought $INBX (top trade: $305K) One buy can be noise. 2 wallets reaching for the same stock in the same window — that's the filing I read twice.
September 29, 2026 at 2:00 PM
2 insiders at Inhibrx Biosciences, Inc. just bought $INBX (top trade: $305K) One buy can be noise. 2 wallets reaching for the same stock in the same window — that's the filing I read twice.
The CEO of Inhibrx Biosciences bought ~$450K of his own stock yesterday — in two separate purchases, same day, both discretionary. When a chief executive reaches for his wallet twice before lunch, that's a sentence in itself. ↓
September 29, 2026 at 12:06 PM
The CEO of Inhibrx Biosciences bought ~$450K of his own stock yesterday — in two separate purchases, same day, both discretionary. When a chief executive reaches for his wallet twice before lunch, that's a sentence in itself. ↓
🔴 Inhibrx Biosciences has a Form 4 dated Sept. 28. The free headline stops there. No shares, price, insider, or transaction type—just a label pointing to a filing. The filing may disclose the trade; this article charges readers to find out what it was.
September 29, 2026 at 10:51 AM
🔴 Inhibrx Biosciences has a Form 4 dated Sept. 28. The free headline stops there. No shares, price, insider, or transaction type—just a label pointing to a filing. The filing may disclose the trade; this article charges readers to find out what it was.
🧵 2/5 🧩 The Setup
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious diseases. Director Jon Faiz Kayyem's half-million-dollar purchase adds a notable insider-conviction signal to an already volatile biotech story.
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious diseases. Director Jon Faiz Kayyem's half-million-dollar purchase adds a notable insider-conviction signal to an already volatile biotech story.
The Insomniac Hedge Fund Guy
The Insomniac Hedge Fund Guy
buff.ly
September 28, 2026 at 10:07 PM
🧵 2/5 🧩 The Setup
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious diseases. Director Jon Faiz Kayyem's half-million-dollar purchase adds a notable insider-conviction signal to an already volatile biotech story.
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious diseases. Director Jon Faiz Kayyem's half-million-dollar purchase adds a notable insider-conviction signal to an already volatile biotech story.
🧵 1/5 🧬 Inhibrx Biosciences Inc. ($INBX)—INSIDER BUY Alert
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00, for an estimated $500,000.
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00, for an estimated $500,000.
September 28, 2026 at 10:07 PM
🧵 1/5 🧬 Inhibrx Biosciences Inc. ($INBX)—INSIDER BUY Alert
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00, for an estimated $500,000.
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00, for an estimated $500,000.
📈 Insider Cluster Buy
3 insiders at Inhibrx Biosciences, Inc. ($INBX) bought $1.5M in shares over 7 days.
https://earningsfeed.com/companies/2007919-inbx-inhibrx-biosciences-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_buy&utm_content=automated_signal
3 insiders at Inhibrx Biosciences, Inc. ($INBX) bought $1.5M in shares over 7 days.
https://earningsfeed.com/companies/2007919-inbx-inhibrx-biosciences-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_buy&utm_content=automated_signal
September 28, 2026 at 9:55 PM
📈 Insider Cluster Buy
3 insiders at Inhibrx Biosciences, Inc. ($INBX) bought $1.5M in shares over 7 days.
https://earningsfeed.com/companies/2007919-inbx-inhibrx-biosciences-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_buy&utm_content=automated_signal
3 insiders at Inhibrx Biosciences, Inc. ($INBX) bought $1.5M in shares over 7 days.
https://earningsfeed.com/companies/2007919-inbx-inhibrx-biosciences-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_buy&utm_content=automated_signal
🚨 $INBX
On September 28, 2026, Inhibrx Biosciences, Inc. posted an updated copy of its corporate presentation to the “Investors” tab of its website at www.inhibrx.com.
On September 28, 2026, Inhibrx Biosciences, Inc. posted an updated copy of its corporate presentation to the “Investors” tab of its website at www.inhibrx.com.
SEC Filing: INBX
Click to view the official SEC document.
www.sec.gov
September 28, 2026 at 9:05 PM
🚨 $INBX
On September 28, 2026, Inhibrx Biosciences, Inc. posted an updated copy of its corporate presentation to the “Investors” tab of its website at www.inhibrx.com.
On September 28, 2026, Inhibrx Biosciences, Inc. posted an updated copy of its corporate presentation to the “Investors” tab of its website at www.inhibrx.com.
$INBX: Jon Kayyem dropped $500K on Inhibrx, a biotech. Half a million of his own money on a drug developer — that's either conviction or a very expensive habit. His three past buys averaged +6.4%. One caveat: someone filed paperwork to sell soon.
September 25, 2026 at 12:06 PM
$INBX: Jon Kayyem dropped $500K on Inhibrx, a biotech. Half a million of his own money on a drug developer — that's either conviction or a very expensive habit. His three past buys averaged +6.4%. One caveat: someone filed paperwork to sell soon.
🧵 2/5 🧩 The Setup
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious diseases, including cancer.
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious diseases, including cancer.
The Insomniac Hedge Fund Guy
The Insomniac Hedge Fund Guy
buff.ly
September 23, 2026 at 10:07 PM
🧵 2/5 🧩 The Setup
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious diseases, including cancer.
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious diseases, including cancer.
🧵 1/5 🧬 Inhibrx Biosciences Inc. ($INBX)—INSIDER BUY Alert
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00 (~$0.50M).
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00 (~$0.50M).
September 23, 2026 at 10:07 PM
🧵 1/5 🧬 Inhibrx Biosciences Inc. ($INBX)—INSIDER BUY Alert
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00 (~$0.50M).
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00 (~$0.50M).
Inhibrx Founder & CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors? share.google/yIHSAM276Yqq...
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
Motley Fool Press Release.
share.google
September 16, 2026 at 3:29 AM
Inhibrx Founder & CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors? share.google/yIHSAM276Yqq...
🧵 2/5 🧩 The Setup
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious and life-threatening diseases, with its pipeline focused on oncology and other high-need therapeutic areas.
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious and life-threatening diseases, with its pipeline focused on oncology and other high-need therapeutic areas.
Insider Buying Week 09-11-26 Following the Smart Money: This Week’s Notable Insider Buys
Following the Smart Money: This Week’s Notable Insider Buys When corporate insiders spend millions of their own money on their company’s stock, investors pay attention. Last week saw heavy conviction…
insomniachedge.com
September 14, 2026 at 5:23 PM
🧵 2/5 🧩 The Setup
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious and life-threatening diseases, with its pipeline focused on oncology and other high-need therapeutic areas.
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious and life-threatening diseases, with its pipeline focused on oncology and other high-need therapeutic areas.
🧵 1/5 🧬 Inhibrx Biosciences Inc. ($INBX)—INSIDER BUY Alert
Director Douglas Forsyth bought 2,500 shares at $114.65 (~$0.29M), while CEO Mark Lappe bought 25,000 shares at $105.82 (~$2.65M).
Director Douglas Forsyth bought 2,500 shares at $114.65 (~$0.29M), while CEO Mark Lappe bought 25,000 shares at $105.82 (~$2.65M).
Insider Buying Week 09-11-26 Following the Smart Money: This Week’s Notable Insider Buys
Following the Smart Money: This Week’s Notable Insider Buys When corporate insiders spend millions of their own money on their company’s stock, investors pay attention. Last week saw heavy conviction…
insomniachedge.com
September 14, 2026 at 5:23 PM
🧵 1/5 🧬 Inhibrx Biosciences Inc. ($INBX)—INSIDER BUY Alert
Director Douglas Forsyth bought 2,500 shares at $114.65 (~$0.29M), while CEO Mark Lappe bought 25,000 shares at $105.82 (~$2.65M).
Director Douglas Forsyth bought 2,500 shares at $114.65 (~$0.29M), while CEO Mark Lappe bought 25,000 shares at $105.82 (~$2.65M).
7 insiders at Inhibrx Biosciences, Inc. just bought $INBX (top trade: $665K) One buy can be noise. 7 wallets reaching for the same stock in the same window — that's the filing I read twice.
September 9, 2026 at 2:00 PM
7 insiders at Inhibrx Biosciences, Inc. just bought $INBX (top trade: $665K) One buy can be noise. 7 wallets reaching for the same stock in the same window — that's the filing I read twice.
$INBX — Inhibrx Biosciences. Mark Lappe, the CEO, bought $665K and then came back the same day for another $585K. Two separate purchases, $1.25M total, no pre-arranged plan. When the person running the company doubles down on himself, that's worth reading. ↓
September 9, 2026 at 12:05 PM
$INBX — Inhibrx Biosciences. Mark Lappe, the CEO, bought $665K and then came back the same day for another $585K. Two separate purchases, $1.25M total, no pre-arranged plan. When the person running the company doubles down on himself, that's worth reading. ↓
Inhibrx Insiders Report About $3.5 Million of Open-Market Stock Purchases Three Inhibrx insiders filed Form 4s reporting open-market purchases of 32,500 shares...
https://www.narrowit.com/news/inhibrx-insiders-buy-3-5-million-stock-form-4-2026-09-08
#InhibrxBiosciences #INBX #Form4 #InsiderBuying
https://www.narrowit.com/news/inhibrx-insiders-buy-3-5-million-stock-form-4-2026-09-08
#InhibrxBiosciences #INBX #Form4 #InsiderBuying
Inhibrx CEO and Directors Disclose $3.5 Million of Stock Buying | Narrowit.com
Three Inhibrx insiders reported open-market purchases of 32,500 shares at a combined disclosed cost of approximately $3.5 million.
www.narrowit.com
September 9, 2026 at 12:28 AM
Inhibrx Insiders Report About $3.5 Million of Open-Market Stock Purchases Three Inhibrx insiders filed Form 4s reporting open-market purchases of 32,500 shares...
https://www.narrowit.com/news/inhibrx-insiders-buy-3-5-million-stock-form-4-2026-09-08
#InhibrxBiosciences #INBX #Form4 #InsiderBuying
https://www.narrowit.com/news/inhibrx-insiders-buy-3-5-million-stock-form-4-2026-09-08
#InhibrxBiosciences #INBX #Form4 #InsiderBuying
Inhibrx touts HNSCC subgroup data, eyes accelerated pathway for OX40 agonist #$INBX #$MRK firstwordpharma.com/story/7963969
September 8, 2026 at 11:08 PM
Inhibrx touts HNSCC subgroup data, eyes accelerated pathway for OX40 agonist #$INBX #$MRK firstwordpharma.com/story/7963969
📈 Insider Cluster Buy
3 insiders at Inhibrx Biosciences, Inc. ($INBX) bought $3.5M in shares over 7 days.
https://earningsfeed.com/companies/2007919-inbx-inhibrx-biosciences-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_buy&utm_content=automated_signal
3 insiders at Inhibrx Biosciences, Inc. ($INBX) bought $3.5M in shares over 7 days.
https://earningsfeed.com/companies/2007919-inbx-inhibrx-biosciences-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_buy&utm_content=automated_signal
September 8, 2026 at 9:30 PM
📈 Insider Cluster Buy
3 insiders at Inhibrx Biosciences, Inc. ($INBX) bought $3.5M in shares over 7 days.
https://earningsfeed.com/companies/2007919-inbx-inhibrx-biosciences-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_buy&utm_content=automated_signal
3 insiders at Inhibrx Biosciences, Inc. ($INBX) bought $3.5M in shares over 7 days.
https://earningsfeed.com/companies/2007919-inbx-inhibrx-biosciences-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_buy&utm_content=automated_signal
📄 #INBX 10-Q — what changed
MD&A now says: "20 ozekibart (INBRX-109) Ozekibart is a precisely engineered tetravalent death receptor 5, or DR5, agonist currently being evaluated in patients diagnosed with colorectal cancer, Ewing sarcoma, chondrosarcoma, and certain other solid tumor types."
📈 Full
MD&A now says: "20 ozekibart (INBRX-109) Ozekibart is a precisely engineered tetravalent death receptor 5, or DR5, agonist currently being evaluated in patients diagnosed with colorectal cancer, Ewing sarcoma, chondrosarcoma, and certain other solid tumor types."
📈 Full
FormDelta — Insider Trading Alerts
What Inhibrx Biosciences, Inc. changed in their own words, quarter over quarter.
www.formdelta.com
September 8, 2026 at 8:07 PM
📄 #INBX 10-Q — what changed
MD&A now says: "20 ozekibart (INBRX-109) Ozekibart is a precisely engineered tetravalent death receptor 5, or DR5, agonist currently being evaluated in patients diagnosed with colorectal cancer, Ewing sarcoma, chondrosarcoma, and certain other solid tumor types."
📈 Full
MD&A now says: "20 ozekibart (INBRX-109) Ozekibart is a precisely engineered tetravalent death receptor 5, or DR5, agonist currently being evaluated in patients diagnosed with colorectal cancer, Ewing sarcoma, chondrosarcoma, and certain other solid tumor types."
📈 Full
🚨 $INBX
On September 8, 2026, Inhibrx Biosciences, Inc. issued a press release announcing clinical updates on INBRX-106 in first-line head and neck squamous cell carcinoma (HNSCC), as discussed in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99...
On September 8, 2026, Inhibrx Biosciences, Inc. issued a press release announcing clinical updates on INBRX-106 in first-line head and neck squamous cell carcinoma (HNSCC), as discussed in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99...
SEC Filing: INBX
Click to view the official SEC document.
www.sec.gov
September 8, 2026 at 8:02 PM
🚨 $INBX
On September 8, 2026, Inhibrx Biosciences, Inc. issued a press release announcing clinical updates on INBRX-106 in first-line head and neck squamous cell carcinoma (HNSCC), as discussed in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99...
On September 8, 2026, Inhibrx Biosciences, Inc. issued a press release announcing clinical updates on INBRX-106 in first-line head and neck squamous cell carcinoma (HNSCC), as discussed in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99...